Danaher (NYSE:DHR) Price Target Raised to $290.00 at Citigroup

Danaher (NYSE:DHR) had its price objective upped by research analysts at Citigroup from $280.00 to $290.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the conglomerate’s stock. Citigroup’s price target would indicate a potential upside of 15.96% from the company’s previous close.

DHR has been the topic of several other reports. Robert W. Baird increased their price objective on Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Bank of America raised their price target on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research report on Wednesday. Barclays boosted their price target on shares of Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Finally, TD Cowen boosted their target price on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday. Six research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus target price of $270.00.

Danaher Stock Performance

DHR stock traded down $3.02 during midday trading on Wednesday, reaching $250.09. 1,490,416 shares of the company were exchanged, compared to its average volume of 2,760,572. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.68 and a quick ratio of 1.37. The business has a 50-day moving average price of $248.95 and a two-hundred day moving average price of $230.64. Danaher has a one year low of $182.09 and a one year high of $259.00. The firm has a market capitalization of $185.20 billion, a price-to-earnings ratio of 39.12, a price-to-earnings-growth ratio of 3.96 and a beta of 0.83.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The company had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a return on equity of 12.25% and a net margin of 17.26%. The business’s revenue for the quarter was down 2.6% compared to the same quarter last year. During the same period in the previous year, the business posted $2.36 EPS. Equities research analysts forecast that Danaher will post 7.62 EPS for the current year.

Insider Activity at Danaher

In other news, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the completion of the sale, the senior vice president now directly owns 38,102 shares of the company’s stock, valued at $9,601,704. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, Director Teri List sold 3,289 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $248.32, for a total transaction of $816,724.48. Following the sale, the director now owns 19,726 shares in the company, valued at $4,898,360.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Daniel Raskas sold 23,757 shares of the firm’s stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $252.00, for a total value of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,957 shares of company stock valued at $8,265,802. 10.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Danaher

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP lifted its position in shares of Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after acquiring an additional 2,998,161 shares during the period. Price T Rowe Associates Inc. MD increased its stake in shares of Danaher by 10.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock valued at $3,876,694,000 after buying an additional 1,619,586 shares during the period. Capital International Investors grew its stake in Danaher by 9.1% during the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock worth $3,691,735,000 after purchasing an additional 1,334,781 shares during the period. Bank of New York Mellon Corp grew its stake in Danaher by 6.5% during the third quarter. Bank of New York Mellon Corp now owns 8,183,501 shares of the conglomerate’s stock worth $2,030,327,000 after purchasing an additional 502,868 shares during the period. Finally, Northern Trust Corp grew its stake in Danaher by 1.7% in the third quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock valued at $2,009,789,000 after acquiring an additional 134,905 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.